[go: up one dir, main page]

GT200800279A - Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida - Google Patents

Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida

Info

Publication number
GT200800279A
GT200800279A GT200800279A GT200800279A GT200800279A GT 200800279 A GT200800279 A GT 200800279A GT 200800279 A GT200800279 A GT 200800279A GT 200800279 A GT200800279 A GT 200800279A GT 200800279 A GT200800279 A GT 200800279A
Authority
GT
Guatemala
Prior art keywords
methyl
etil
hydroxi
indol
salts
Prior art date
Application number
GT200800279A
Other languages
English (en)
Inventor
Acemoglu Murat
Joginder S Bajwa
Karpinski Piotr
Papoutsakis Dimitris
Slade Joel
Stowasser Frank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800279(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800279A publication Critical patent/GT200800279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A SALES DE N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-IL)ETIL]AMINO]METIL]
GT200800279A 2006-06-12 2008-12-10 Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida GT200800279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
GT200800279A true GT200800279A (es) 2010-06-16

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800279A GT200800279A (es) 2006-06-12 2008-12-10 Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida

Country Status (37)

Country Link
US (3) US20090197936A1 (es)
EP (1) EP2032531B1 (es)
JP (2) JP2009540005A (es)
KR (2) KR20090026281A (es)
AR (1) AR061298A1 (es)
AU (1) AU2007257962B2 (es)
BR (1) BRPI0712771A2 (es)
CA (1) CA2654439C (es)
CL (1) CL2007001692A1 (es)
CR (1) CR10439A (es)
DK (1) DK2032531T3 (es)
EA (1) EA015212B1 (es)
EC (1) ECSP088979A (es)
ES (1) ES2570934T3 (es)
GE (1) GEP20105125B (es)
GT (1) GT200800279A (es)
HN (1) HN2008001859A (es)
HR (1) HRP20160291T1 (es)
HU (1) HUE027126T2 (es)
IL (1) IL195087A (es)
JO (1) JO3138B1 (es)
MA (1) MA30563B1 (es)
ME (1) ME00531B (es)
MX (1) MX2008015901A (es)
MY (1) MY147345A (es)
NO (1) NO341871B1 (es)
NZ (1) NZ572547A (es)
PE (1) PE20080937A1 (es)
PL (1) PL2032531T3 (es)
RS (1) RS54640B1 (es)
SI (1) SI2032531T1 (es)
SM (1) SMP200900002B (es)
SV (1) SV2008003126A (es)
TN (1) TNSN08501A1 (es)
TW (1) TWI409254B (es)
UY (1) UY30403A1 (es)
WO (1) WO2007146715A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017984B1 (ru) 2006-06-12 2013-04-30 Новартис Аг Кристаллические безводные формы лактата n-гидрокси-3-[4-[[[2-(2-метил-1h-индол-3-ил)этил]амино]метил]фенил]-2e-2-акриламида
KR20090098920A (ko) * 2007-01-10 2009-09-17 노파르티스 아게 데아세틸라제 억제제의 제제
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat
EP4126188A1 (en) 2020-03-25 2023-02-08 Boston Scientific Scimed Inc. Medical device for treating decompensated heart failure
BR112022021712A2 (pt) 2020-04-30 2022-12-06 Exelixis Inc Processos para a preparação de um inibidor de quinase
CN116648449A (zh) * 2020-10-28 2023-08-25 维拉克塔附属公司 Hdac抑制剂固态形式

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2005013958A1 (en) * 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
EA017984B1 (ru) * 2006-06-12 2013-04-30 Новартис Аг Кристаллические безводные формы лактата n-гидрокси-3-[4-[[[2-(2-метил-1h-индол-3-ил)этил]амино]метил]фенил]-2e-2-акриламида
EP2032532B8 (en) * 2006-06-12 2015-07-01 Novartis AG Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

Also Published As

Publication number Publication date
CR10439A (es) 2009-01-15
ES2570934T3 (es) 2016-05-23
KR101629352B1 (ko) 2016-06-13
MX2008015901A (es) 2009-01-12
HK1126496A1 (zh) 2009-09-04
JP2009540005A (ja) 2009-11-19
US20100286409A1 (en) 2010-11-11
EP2032531A1 (en) 2009-03-11
KR20090026281A (ko) 2009-03-12
CL2007001692A1 (es) 2008-05-09
IL195087A0 (en) 2009-08-03
MY147345A (en) 2012-11-30
RS54640B1 (sr) 2016-08-31
HUE027126T2 (en) 2016-08-29
PL2032531T3 (pl) 2016-07-29
WO2007146715A1 (en) 2007-12-21
UY30403A1 (es) 2008-01-31
ME00531B (me) 2011-10-10
MA30563B1 (fr) 2009-07-01
HRP20160291T1 (hr) 2016-04-22
US20110112308A1 (en) 2011-05-12
AU2007257962B2 (en) 2011-06-23
SMP200900002B (it) 2010-01-19
TWI409254B (zh) 2013-09-21
TNSN08501A1 (en) 2010-04-14
AU2007257962A1 (en) 2007-12-21
IL195087A (en) 2012-10-31
PE20080937A1 (es) 2008-08-29
TW200815343A (en) 2008-04-01
EA015212B1 (ru) 2011-06-30
JO3138B1 (ar) 2017-09-20
BRPI0712771A2 (pt) 2012-09-25
NZ572547A (en) 2011-06-30
NO20090128L (no) 2009-03-11
GEP20105125B (en) 2010-11-25
JP5771257B2 (ja) 2015-08-26
KR20150029765A (ko) 2015-03-18
CA2654439A1 (en) 2007-12-21
EA200802382A1 (ru) 2009-06-30
NO341871B1 (no) 2018-02-12
ECSP088979A (es) 2009-01-30
DK2032531T3 (en) 2016-04-11
HN2008001859A (es) 2011-07-19
SMAP200900002A (it) 2009-01-14
JP2013256542A (ja) 2013-12-26
SI2032531T1 (sl) 2016-05-31
SV2008003126A (es) 2011-07-05
US20090197936A1 (en) 2009-08-06
AR061298A1 (es) 2008-08-20
EP2032531B1 (en) 2016-02-10
CA2654439C (en) 2014-08-05

Similar Documents

Publication Publication Date Title
GT200800279A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
HN2007000407A (es) Compuesto de biaril eter urea
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
GT200800281A (es) Procedimiento para hacer sales de n-hidroxi-3-(4-(((2-(2-metil-1h-indol-3-il)-etil)amino)metil)fenil)-2e-2-propenamida
DK2147098T3 (da) Anvendelse af proteinhydrolysater til stabilisering af metalloprotease-detergent-formuleringer
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
HN2009000499A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil} amino)3-fluorofenoxi]-n-metilpiridina-2- carboxamida monohidrato.
UY31463A1 (es) Inhibidores de péptido desformilasa
EP2242362A4 (en) IAP INHIBITORS
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
ATE544769T1 (de) 2-(substituiertes amino)- benzothiazolsulfonamidverbindungen als hiv- protease-inhibitoren
HN2009001436A (es) Nuevo procedimiento de sintesis de la agometatina
JP2009543766A5 (ja) ｍＰＧＥｓ−１阻害剤としての２−アリールインドール誘導体
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
CO7081156A2 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
CR11332A (es) Co-cristales de pirimetanilo y ditianona
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
HN2006035238A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
DK1740708T3 (da) Enzymatisk fremstilling af hydrolyserede lecithinprodukter
ZA200809383B (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide
GT200800282A (es) Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου